Takeda Vietnam
Vietnam
The Representative Office of Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd in Vietnam (Takeda RO Vietnam) was set up in Ho Chi Minh City in November 2014. Takeda RO Vietnam is part of the VIMAS cluster that includes Vietnam, Malaysia and Singapore. Strategic pillars of Vietnam are aligned to global therapeutic areas of focus on Gastroenterology and Oncology. We have been able to respond to the unmet needs of patients with our current PPI (proton pump inhibitor) portfolio and will work to continue to serve GI patients with the recent launch of Dexilant.
Our purpose is to create “Better Health, Better Future” for patients in Vietnam.
Careers
Contact Us
Takeda Viet Nam Pharmaceuticals Limited
Unit 16.1, 16th Floor, The Nexus, 3A-3B Ton Duc Thang Street, Ben Nghe Ward, District 1, Ho Chi Minh City,
The Representative Office of Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd. in Ho Chi Minh City
Unit 16.1, 16th Floor, The Nexus, 3A-3B Ton Duc Thang Street, Ben Nghe Ward, District 1, Ho Chi Minh City,
Phone
+84 28 7308 6868
Email
Additional Information
Updated: 2 November 2023 - It has been brought to our attention that the name and logo of Takeda Pharmaceutical Company Limited have been used without authorization to solicit investments on the TVD-VN platform in attempts to defraud members of the public via notices, scam emails, digital mobile apps, social media platforms, and social messaging apps. These unauthorized individuals have been using the Takeda name and logo to purport to provide opportunities to profit by investing in products and drugs by Takeda. The matter is currently under investigation, and we reserve the right to take legal action on the matter.
Takeda Pharmaceutical Company Limited, Representative Offices of Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd. in Ho Chi Minh City and Hanoi, and any of the Takeda affiliated companies are not in any way affiliated, involved, nor associated with the above scheme or platform.
It is important to note that Takeda would never ask individuals to provide their own money as part of any legitimate research or business opportunity, and Takeda would also never ask any organizations to invest their money through unverified methods without proper documentation and compliance processes. Takeda would advise its partners, healthcare professionals, stakeholders, and the public not to respond to this scheme and report to relevant authorities in case of doubt.